Epigallocatechin-3-gallate protects against cisplatin nephrotoxicity by inhibiting the apoptosis in mouse

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 8, 2014, Pages 4607-4616

  Zou, Peimei ^a   Song, Jian ^a   Jiang, Bei ^a   Pei, Fei ^a   Chen, Binbin ^a   Yang, Xiangdong ^a   Liu, Guangyi ^a,b   Hu, Zhao ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Cisplatin (CP); Epigallocatechin 3 gallate (EGCG); Mouse; Renal

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; CATECHIN; CISPLATIN; EPIGALLOCATECHIN GALLATE;

ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; KIDNEY; KIDNEY DISEASES; MALE; MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CATECHIN; CISPLATIN; DISEASE MODELS, ANIMAL; KIDNEY; KIDNEY DISEASES; MALE; MICE; MICE, INBRED C57BL;

EID: 84906958393     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Hartmann JT, Fels LM, Knop S, Stolt H, Kanz L and Bokemeyer C. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs 2000; 18: 281-289.
2. Hartmann JT and Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother 2003; 4: 889-901.
3. Arany I and Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23: 460-464.
4. Sastry J and Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 2005; 22: 441-445.
5. Choi YJ, Baranowska-Daca E, Nguyen V, Koji T, Ballantyne CM, Sheikh-Hamad D, Suki WN and Truong LD. Mechanism of chronic obstructive uropathy: increased expression of apoptosis-promoting molecules. Kidney Int 2000; 58: 1481-1491.
6. Truong LD, Choi YJ, Tsao CC, Ayala G, Sheikh-Hamad D, Nassar G and Suki WN. Renal cell apoptosis in chronic obstructive uropathy: the roles of caspases. Kidney Int 2001; 60: 924-934.
7. Hauser P and Oberbauer R. Tubular apoptosis in the pathophysiology of renal disease. Wien Klin Wochenschr 2002; 114: 671-677.
8. Jiang M, Wei Q, Wang J, Du Q, Yu J, Zhang L and Dong Z. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 2006; 25: 4056-4066.
9. Liu H and Baliga R. Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis. J Am Soc Nephrol 2005; 16: 1985-1992.
10. Park MS, De Leon M and Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 2002; 13: 858-865.
11. Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Kishihara K, Hirakata H and Iida M. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 2003; 63: 72-82.
12. Razzaque MS, Koji T, Kumatori A and Taguchi T. Cisplatin-induced apoptosis in human proximal tubular epithelial cells is associated with the activation of the Fas/Fas ligand system. Histochem Cell Biol 1999; 111: 359-365.
13. Schelling JR, Nkemere N, Kopp JB and Cleveland RP. Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab Invest 1998; 78: 813-824.
14. Tsuruya K, Tokumoto M, Ninomiya T, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Hirakata H and Iida M. Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways. Am J Physiol Renal Physiol 2003; 285: F208-218.
15. Camano S, Lazaro A, Moreno-Gordaliza E, Torres AM, de Lucas C, Humanes B, Lazaro JA, Milagros Gomez-Gomez M, Bosca L and Tejedor A. Cilastatin attenuates cisplatin-induced proximal tubular cell damage. J Pharmacol Exp Ther 2010; 334: 419-429.
16. Dogukan A, Tuzcu M, Agca CA, Gencoglu H, Sahin N, Onderci M, Ozercan IH, Ilhan N, Kucuk O and Sahin K. A tomato lycopene complex protects the kidney from cisplatin-induced injury via affecting oxidative stress as well as Bax, Bcl-2, and HSPs expression. Nutr Cancer 2011; 63: 427-434.
17. Domitrovic R, Potocnjak I, Crncevic-Orlic Z and Skoda M. Nephroprotective activities of rosmarinic acid against cisplatin-induced kidney injury in mice. Food Chem Toxicol 2014; 66: 321-328.
18. Gao Z, Liu G, Hu Z, Li X, Yang X, Jiang B and Li X. Grape seed proanthocyanidin extract protects from cisplatin-induced nephrotoxicity by inhibiting endoplasmic reticulum stress-induced apoptosis. Mol Med Rep 2014; 9: 801-807.
19. Song J, Liu D, Feng L, Zhang Z, Jia X and Xiao W. Protective Effect of Standardized Extract of Ginkgo biloba against Cisplatin-Induced Nephrotoxicity. Evid Based Complement Alternat Med 2013; 2013: 846126.
20. Khurana S, Hollingsworth A, Piche M, Venkataraman K, Kumar A, Ross GM and Tai TC. Antiapoptotic actions of methyl gallate on neonatal rat cardiac myocytes exposed to H2O2. Oxid Med Cell Longev 2014; 2014: 657512.
21. Kim KC and Lee C. Reversal of Cisplatin resistance by epigallocatechin gallate is mediated by downregulation of axl and tyro 3 expression in human lung cancer cells. Korean J Physiol Pharmacol 2014; 18: 61-66.
22. Qi H, Abe N, Zhu B, Murata Y and Nakamura Y. (-)-Epigallocatechin-3-Gallate Ameliorates Photodynamic Therapy Responses in an In Vitro T Lymphocyte Model. Phytother Res 2014; [Epub ahead of print].
23. Chen R, Hollborn M, Grosche A, Reichenbach A, Wiedemann P, Bringmann A and Kohen L. Effects of the vegetable polyphenols epigallocatechin-3-gallate, luteolin, apigenin, myricetin, quercetin, and cyanidin in primary cultures of human retinal pigment epithelial cells. Mol Vis 2014; 20: 242-258.
24. Landis-Piwowar KR, Huo C, Chen D, Milacic V, Shi G, Chan TH and Dou QP. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res 2007; 67: 4303-4310.
25. El-Mowafy AM, Salem HA, Al-Gayyar MM, El-Mesery ME and El-Azab MF. Evaluation of renal protective effects of the green-tea (EGCG) and red grape resveratrol: role of oxidative stress and inflammatory cytokines. Nat Prod Res 2011; 25: 850-856.
26. Nagle DG, Ferreira D and Zhou YD. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry 2006; 67: 1849-1855.
27. Peng A, Ye T, Rakheja D, Tu Y, Wang T, Du Y, Zhou JK, Vaziri ND, Hu Z, Mohan C and Zhou XJ. The green tea polyphenol (-)-epigallocatechin-3-gallate ameliorates experimental immune-mediated glomerulonephritis. Kidney Int 2011; 80: 601-611.
28. Sahin K, Tuzcu M, Gencoglu H, Dogukan A, Timurkan M, Sahin N, Aslan A and Kucuk O. Epigallocatechin-3-gallate activates Nrf2/HO-1 signaling pathway in cisplatin-induced nephrotoxicity in rats. Life Sci 2010; 87: 240-245.
29. El-Mowafy AM, Al-Gayyar MM, Salem HA, El-Mesery ME and Darweish MM. Novel chemotherapeutic and renal protective effects for the green tea (EGCG): role of oxidative stress and inflammatory-cytokine signaling. Phytomedicine 2010; 17: 1067-1075.
30. Rosenberg B, Vancamp L and Krigas T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698-699.
31. Wang D and Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307-320.
32. Miller RP, Tadagavadi RK, Ramesh G and Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2010; 2: 2490-2518.
33. Blachley JD and Hill JB. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 1981; 95: 628-632.
34. Pabla N and Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73: 994-1007.
35. Yao X, Panichpisal K, Kurtzman N and Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007; 334: 115-124.
36. Linkermann A, Himmerkus N, Rolver L, Keyser KA, Steen P, Brasen JH, Bleich M, Kunzendorf U and Krautwald S. Renal tubular Fas ligand mediates fratricide in cisplatin-induced acute kidney failure. Kidney Int 2011; 79: 169-178.
37. Goldstein JC, Waterhouse NJ, Juin P, Evan GI and Green DR. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol 2000; 2: 156-162.
38. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ and Schlesinger PH. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000; 7: 1166-1173.
39. Jiang M, Wang CY, Huang S, Yang T and Dong Z. Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway. Am J Physiol Renal Physiol 2009; 296: F983-993.
40. Brenner C and Kroemer G. Apoptosis. Mitochondria--the death signal integrators. Science 2000; 289: 1150-1151.
41. Wei Q, Dong G, Franklin J and Dong Z. The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 2007; 72: 53-62.
42. Cummings BS and Schnellmann RG. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 2002; 302: 8-17.
43. Jiang M, Yi X, Hsu S, Wang CY and Dong Z. Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am J Physiol Renal Physiol 2004; 287: F1140-1147.
44. Wei Q, Dong G, Yang T, Megyesi J, Price PM and Dong Z. Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 2007; 293: F1282-1291.
45. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R and Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998; 282: 290-293.
46. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M and Krammer PH. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998; 188: 2033-2045.
47. Chandel NS, Vander Heiden MG, Thompson CB and Schumacker PT. Redox regulation of p53 during hypoxia. Oncogene 2000; 19: 3840-3848.
48. Miyashita T and Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.